Serum 1-84 and 7-84 Parathyroid Hormone Concentrations and Bone in Patients with Primary Hyperparathyroidism

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2008 Jul 12

PMID 18618138

Authors

A Blachowicz

W Chudzinski

I Nawrot

B Kryszalowicz

U Spiechowicz

J Szmidt

A Wiecek

E Franek

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Parathyroid hormone (PTH) acts on bone as both anabolic and catabolic factor. It includes two fractions: 1-84 (cyclase activating PTH, CAP) which increases bone turnover and serum calcium, and 7-84 (cyclase inactivating PTH, CIP) acting the opposite way. The aim of this study was to establish whether bone mineral density (BMD) and turnover in patients' primary hyperparathyroidism (HPT) are dependent on CAP and CIP concentrations.

Patients/methods: Thirty-one patients with HPT and 29 appropriately matched controls were examined. Parameters of calcium-phosphate homeostasis and BMD were estimated.

Results: BMD of radius shaft was lower in patients with HPT as compared with controls, whereas BMD of spine and ultradistal radius were similar. Serum calcium, bone alkaline phosphatase, total PTH, 1-84 PTH, and 7-84 PTH were higher in HPT patients, whereas serum phosphate was lower and beta cross-laps similar. Both total PTH and CAP correlated significantly with BMD of radius shaft and serum calcium concentration, but not with other examined parameters.

Conclusion: Total and 1-84 PTH are similarly associated with examined parameters in patients with HPT. Thus, determination of serum CAP concentration does not seem to have advantages over total PTH with regard to bone mineral density and bone turnover assessment in those patients.

References

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

Silverberg S, Bilezikian J . Evaluation and management of primary hyperparathyroidism. J Clin Endocrinol Metab. 1996; 81(6):2036-40. DOI: 10.1210/jcem.81.6.8964825. View

Harms H, Kaptaina U, Kulpmann W, Brabant G, Hesch R . Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab. 1989; 69(4):843-51. DOI: 10.1210/jcem-69-4-843. View

Gao P, Scheibel S, DAmour P, John M, Rao S, Schmidt-Gayk H . Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001; 16(4):605-14. DOI: 10.1359/jbmr.2001.16.4.605. View

Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai G . PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002; 40(2):348-54. DOI: 10.1053/ajkd.2002.34519. View

Reichel H, Esser A, Roth H, Schmidt-Gayk H . Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant. 2003; 18(4):759-68. DOI: 10.1093/ndt/gfg144. View

Dai J, He P, Chen X, Greenfield E . TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone. 2005; 38(4):509-20. DOI: 10.1016/j.bone.2005.10.007. View

Tobias J, Cooper C . PTH/PTHrP activity and the programming of skeletal development in utero. J Bone Miner Res. 2004; 19(2):177-82. DOI: 10.1359/JBMR.0301235. View

Slatopolsky E, Finch J, CLAY P, Martin D, Sicard G, Singer G . A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000; 58(2):753-61. DOI: 10.1046/j.1523-1755.2000.00222.x. View

10.

Huan J, Olgaard K, Nielsen L, Lewin E . Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol. 2006; 17(7):1923-30. DOI: 10.1681/ASN.2005101136. View

11.

Khan A, Bilezikian J . Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ. 2000; 163(2):184-7. PMC: 80211. View

12.

Roth H, Albert C, Schmidt-Gayk H . New assays for intact parathyroid hormone and their clinical relevance for the diagnosis of hyperparathyroidism. Clin Lab. 2002; 48(11-12):589-93. View

13.

Schmitt C, Huber D, Mehls O, Maiwald J, Stein G, Veldhuis J . Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol. 1998; 9(10):1832-44. DOI: 10.1681/ASN.V9101832. View

14.

Monier-Faugere M, Geng Z, Mawad H, FRIEDLER R, Gao P, Cantor T . Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001; 60(4):1460-8. DOI: 10.1046/j.1523-1755.2001.00949.x. View

15.

Qin L, Raggatt L, Partridge N . Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15(2):60-5. DOI: 10.1016/j.tem.2004.01.006. View

16.

Reeve J, Meunier P, Parsons J, Bernat M, BIJVOET O, Courpron P . Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980; 280(6228):1340-4. PMC: 1601798. DOI: 10.1136/bmj.280.6228.1340. View

17.

Samuels M, Veldhuis J, Kramer P, Urban R, Bauer R, Mundy G . Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res. 1997; 12(4):616-23. DOI: 10.1359/jbmr.1997.12.4.616. View

18.

Hock J, Gera I . Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res. 1992; 7(1):65-72. DOI: 10.1002/jbmr.5650070110. View

19.

Sneddon W, Yang Y, Ba J, Harinstein L, Friedman P . Extracellular signal-regulated kinase activation by parathyroid hormone in distal tubule cells. Am J Physiol Renal Physiol. 2006; 292(3):F1028-34. DOI: 10.1152/ajprenal.00288.2006. View